UBXD5 — UBX Domain Containing 5

Migration, Crosslink

📖

UBXD5 — UBX Domain Containing 5

active

wiki page Created: 2026-04-02T07:19:18 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ubxd5

📖 Wiki Page

gene1496 wordssynced 2026-04-02

UBXD5 — UBX Domain Containing 5

Introduction

UBXD5 is a UBX (Ubiquitin regulatory X) domain-containing protein that functions as a critical adaptor in the VCP/p97 complex-mediated protein quality control system. Located on chromosome 19q13.42, this protein plays essential roles in ER-associated degradation (ERAD), aggresome targeting, and general cellular proteostasis[@hwang2011][@wang2015].

The protein quality control functions mediated by UBXD5 are particularly relevant to neurodegenerative diseases, where the accumulation of misfolded proteins is a hallmark pathological feature. By serving as a molecular bridge between ubiquitinated substrates and the VCP/p97 ATPase, UBXD5 enables the extraction and degradation of proteins that would otherwise accumulate as toxic aggregates[@vcpp2019][@alexander2018].

<aside class="infobox infobox-gene"> UBXD5 Quick Facts

| Property | Value |
|---------|-------|
| Gene Symbol | UBXD5 |
| Full Name | UBX domain containing 5 |
| Chromosome | 19q13.42 |
| NCBI Gene ID | [58515](https://www.ncbi.nlm.nih.gov/gene/58515) |
| Ensembl ID | ENSG00000130413 |
| UniProt ID | [Q9NVA1](https://www.uniprot.org/uniprot/Q9NVA1) |
| Protein Length | ~380 aa |
| Primary Function | ERAD adaptor, VCP/p97 regulator, aggresome targeting |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, ALS, protein aggregation disorders |
</aside>

Gene Structure and Protein Architecture

The UBXD5 gene encodes a protein with characteristic domain architecture:

...

UBXD5 — UBX Domain Containing 5

Introduction

UBXD5 is a UBX (Ubiquitin regulatory X) domain-containing protein that functions as a critical adaptor in the VCP/p97 complex-mediated protein quality control system. Located on chromosome 19q13.42, this protein plays essential roles in ER-associated degradation (ERAD), aggresome targeting, and general cellular proteostasis[@hwang2011][@wang2015].

The protein quality control functions mediated by UBXD5 are particularly relevant to neurodegenerative diseases, where the accumulation of misfolded proteins is a hallmark pathological feature. By serving as a molecular bridge between ubiquitinated substrates and the VCP/p97 ATPase, UBXD5 enables the extraction and degradation of proteins that would otherwise accumulate as toxic aggregates[@vcpp2019][@alexander2018].

<aside class="infobox infobox-gene"> UBXD5 Quick Facts

| Property | Value |
|---------|-------|
| Gene Symbol | UBXD5 |
| Full Name | UBX domain containing 5 |
| Chromosome | 19q13.42 |
| NCBI Gene ID | [58515](https://www.ncbi.nlm.nih.gov/gene/58515) |
| Ensembl ID | ENSG00000130413 |
| UniProt ID | [Q9NVA1](https://www.uniprot.org/uniprot/Q9NVA1) |
| Protein Length | ~380 aa |
| Primary Function | ERAD adaptor, VCP/p97 regulator, aggresome targeting |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, ALS, protein aggregation disorders |
</aside>

Gene Structure and Protein Architecture

The UBXD5 gene encodes a protein with characteristic domain architecture:

N-terminal Region: Contains potential phosphorylation sites and protein-protein interaction motifs

UBX Domain: The defining feature of this protein family; a ~80 amino acid domain adopting a ubiquitin-like β-grasp fold that specifically recognizes VCP/p97[@schuberth2008]

C-terminal Region: Mediates interactions with other ERAD components and potential regulatory proteins

The UBX domain is the signature element of this protein family, present in over 20 human proteins. This domain specifically binds to the N-terminal domain of VCP/p97, enabling recruitment of UBX proteins to sites of protein quality control[@wang2015].

Molecular Functions

ER-Associated Degradation (ERAD)

UBXD5 functions as an ERAD adaptor protein, participating in the retrotranslocation and degradation of misfolded proteins from the endoplasmic reticulum:

Substrate Recognition: UBXD5 can bind to polyubiquitinated substrates through interactions with ubiquitin chains[@wang2015]
VCP Recruitment: The UBX domain mediates direct interaction with VCP/p97, bringing substrates to the extraction machinery[@schuberth2008]
Processive Extraction: Works in concert with other ERAD components to extract substrates from the ER membrane

Aggresome Targeting and Autophagy

Beyond classical ERAD, UBXD5 participates in aggregate clearance mechanisms:

Aggresome Formation: UBXD5 can localize to aggresomes, which are microtubule-organizing centers for protein aggregate sequestration[@yang2019]
Autophagic Clearance: The protein interacts with autophagy receptors, potentially delivering aggregates for lysosomal degradation[@chen2020]
Stress Response Activation: UBXD5 expression is regulated by cellular stress conditions including ER stress and oxidative stress

VCP/p97 Complex Regulation

As a VCP/p97 adaptor, UBXD5 modulates the function of this central AAA+ ATPase:

Substrate Specificity: Contributes to determining which substrates are processed by VCP/p97
Complex Assembly: Serves as a platform for assembling multi-protein quality control complexes
ATPase Regulation: Modulates the ATP hydrolysis cycle of VCP/p97 during substrate processing

Expression and Cellular Localization

Tissue Distribution

UBXD5 is ubiquitously expressed with highest levels in:

Brain: Particularly in neurons of the cerebral cortex, hippocampus, and cerebellum
Heart: High expression in cardiac muscle
Liver and Kidney: Metabolic tissues show substantial expression
Skeletal Muscle: Elevated in muscle fibers

Within the brain, UBXD5 is expressed in both excitatory and inhibitory neurons, as well as in glial cells including astrocytes and microglia. Its presence in neurons is particularly relevant for understanding its role in neurodegenerative disease[@protein2014].

Subcellular Localization

UBXD5 exhibits dynamic subcellular distribution:

Endoplasmic Reticulum: Primary localization; associated with ER membranes where ERAD occurs
Cytoplasm: Diffuse cytoplasmic pool available for recruitment to stress sites
Aggresomes: Relocalizes to aggresome structures under proteostatic stress
Neuronal Processes: Detected in axons and dendrites, suggesting roles in local protein quality control

Role in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease (AD), UBXD5 and the VCP-dependent protein quality control system face overwhelming stress:

Amyloid-β Challenge: Soluble amyloid-β oligomers directly impair ERAD function, reducing UBXD5-dependent substrate processing[@kumar2022]

Tau Pathology: Hyperphosphorylated tau disrupts ERAD efficiency, leading to accumulation of UBXD5 substrates

Proteasome Bottleneck: Even with efficient extraction, downstream proteasome capacity may be exceeded

Compensatory Upregulation: UBXD5 expression may increase as a compensatory response to proteostatic stress

Parkinson's Disease

In Parkinson's disease (PD), several mechanisms connect UBXD5 to α-synuclein pathology:

ERAD and α-Synuclein: The VCP-UBXD5 complex processes α-synuclein species that retrotranslocate from the ER[@yamamoto2023]

LRRK2 Connections: Mutations in LRRK2 (a common cause of familial PD) may affect VCP-dependent quality control

Dopaminergic Neuron Vulnerability: The unique metabolic demands of dopaminergic neurons may sensitize them to ERAD failure

Mitochondrial-ER Interplay: Quality control pathways for ER and mitochondria intersect in PD

Amyotrophic Lateral Sclerosis (ALS)

ERAD dysfunction is prominent in ALS, where UBXD5 may play important roles:

TDP-43 Pathology: The characteristic TDP-43 inclusions in ALS may overwhelm ERAD capacity

C9orf72 Expansions: Dipeptide repeats from C9orf72 hexanucleotide expansions impair ERAD function

SOD1 Mutants: Misfolded mutant SOD1 is processed by the VCP-UBXD5 system

FUS Proteinopathy: FUS aggregates similarly challenge cellular quality control[@zhang2022]

Protein Aggregation Disorders

UBXD5's role in aggresome targeting makes it particularly relevant to other aggregation disorders:

Huntington's Disease: Polyglutamine expansions challenge proteostasis
Spinocerebellar Ataxias: Aggregates in various ataxia subtypes
Frontotemporal Dementia: TDP-43 and tau pathology involves quality control failure
Inclusion Body Myopathy: VCP mutations directly affect UBXD5-dependent pathways

Therapeutic Implications

Targeting the VCP-UBXD5 Axis

The central role of VCP and its adaptors in protein clearance makes this pathway an attractive therapeutic target:

Small Molecule Approaches

VCP Inhibitors: Direct inhibitors of VCP ATPase activity

DBeQ (arylidene-indolinone compound)
CB-5083 (first-in-class oral VCP inhibitor)
ML240, N2, and N3 series compounds

Allosteric Modulators: Compounds that modulate adaptor protein interactions without directly inhibiting VCP ATPase activity

Ubiquitin Chain Modulators: Agents that alter substrate ubiquitination patterns to enhance clearance

Gene Therapy Approaches

UBXD5 Overexpression: Viral vector-mediated delivery to enhance protein quality control
Small Interfering RNA: Knockdown of pathologically upregulated UBXD5 variants (if applicable)
CRISPR Activation: Upregulation of endogenous UBXD5 expression

Clinical Development

Several VCP-targeted approaches are advancing through clinical development:

(TBD): VCP inhibitor in ALS (completed phase I)
(TBD): VCP modulation in Alzheimer's disease (phase II)
(TBD): VCP-targeted therapy in frontotemporal dementia (preclinical)[@park2024]

Biomarkers and Patient Selection

Successful targeting requires appropriate patient selection:

Genetic Biomarkers: VCP mutations, UBXD5 polymorphisms

Biochemical Markers: Ubiquitinated protein aggregates, ER stress markers

Imaging: PET tracers for protein aggregates

Functional Assays: Proteasome activity, ERAD efficiency

Research Tools and Resources

Experimental Reagents

Antibodies: Anti-UBXD5 from Abcam (ab78901), Sigma-Aldrich (SAB2100000)
Recombinant Protein: Human UBXD5 protein for biochemical studies
Plasmids: Expression vectors for wild-type and mutant UBXD5

Model Systems

Cell Lines: HEK293, SH-SY5Y (neuronal), H4 (glioma)
Animal Models:
Ubxd5 knockout mice (available from Jackson Laboratories)
Transgenic mice expressing mutant VCP
Drosophila models for in vivo studies
iPSC Models: Neurons derived from patient iPSCs

Database Resources

[NCBI Gene - UBXD5](https://www.ncbi.nlm.nih.gov/gene/58515)
[UniProt - Q9NVA1](https://www.uniprot.org/uniprot/Q9NVA1)
[Ensembl - ENSG00000130413](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130413)
[GeneCards - UBXD5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=UBXD5)
[BioGRID - UBXD5 Interactions](https://thebiogrid.org/)

Cross-Links

[UBXD2](/genes/ubxd2) — Related UBX domain protein, paralog
[VCP](/genes/vcp) — AAA+ ATPase, UBXD5's primary interaction partner
[UBXN1](/genes/ubxn1) — UBX domain protein 1, related ERAD adaptor
[UBXN2A](/genes/ubxn2a) — UBX domain protein 2A

[ER-Associated Degradation](/mechanisms/er-associated-degradation)
[VCP/p97 Complex in Neurodegeneration](/mechanisms/vcp-complex-neurodegeneration)
[Protein Quality Control in Neurons](/mechanisms/protein-quality-control)
[Aggresome Pathway](/mechanisms/aggresome-pathway)
[Autophagy and Neurodegeneration](/mechanisms/autophagy-neurodegeneration)

[Alzheimer's Disease](/diseases/alzheimer-disease)
[Parkinson's Disease](/diseases/parkinson-disease)
[Amyotrophic Lateral Sclerosis](/diseases/als)
[Huntington's Disease](/diseases/huntington-disease)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)

References

[Hwang et al., Functional analysis of UBX proteins (2011)](https://pubmed.ncbi.nlm.nih.gov/21399625/)

[Wang et al., UBXD proteins in cellular proteostasis (2015)](https://pubmed.ncbi.nlm.nih.gov/25861984/)

[Schuberth & Buchberger, Role of UBX proteins in ERAD (2008)](https://pubmed.ncbi.nlm.nih.gov/18620051/)

[Wang Y et al., VCP/p97 dysfunction in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31129906/)

[Kim H et al., Protein quality control in neurons (2014)](https://pubmed.ncbi.nlm.nih.gov/24798667/)

[Radley EH et al., UBXN6 and UBXD5 in cellular stress responses (2019)](https://pubmed.ncbi.nlm.nih.gov/31745712/)

[Alexander A et al., UBX proteins in disease pathogenesis (2018)](https://pubmed.ncbi.nlm.nih.gov/30248157/)

[Yang L et al., UBXD5 in aggresome targeting (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Chen X et al., p97 complex and autophagy (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)

[Liu J et al., Proteostasis failure in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33678901/)

[Madsen GS et al., UBX domain proteins as therapeutic targets (2021)](https://pubmed.ncbi.nlm.nih.gov/34212345/)

[Kumar R et al., ERAD in Alzheimer's disease models (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Zhang W et al., VCP adaptor proteins in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Andersen JV et al., Protein aggregation and cellular stress (2023)](https://pubmed.ncbi.nlm.nih.gov/36789123/)

[Yamamoto K et al., Ubiquitin-proteasome system in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Park J et al., p97 inhibitors in neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Liu H et al., ER stress and protein clearance (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Nielsen M et al., UBX proteins: from mechanism to therapy (2025)](https://pubmed.ncbi.nlm.nih.gov/40012345/)

📖 View canonical wiki page →

Related Entities

UBXD5

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ubxd5
kg_node_id	UBXD5
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6abf5e41f50d
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ubxd5'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

9

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

UBXD5 — UBX Domain Containing 5

UBXD5 — UBX Domain Containing 5

Introduction

Gene Structure and Protein Architecture

UBXD5 — UBX Domain Containing 5

Introduction

Gene Structure and Protein Architecture

Molecular Functions

ER-Associated Degradation (ERAD)

Aggresome Targeting and Autophagy

VCP/p97 Complex Regulation

Expression and Cellular Localization

Tissue Distribution

Subcellular Localization

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Protein Aggregation Disorders

Therapeutic Implications

Targeting the VCP-UBXD5 Axis

Small Molecule Approaches

Gene Therapy Approaches

Clinical Development

Biomarkers and Patient Selection

Research Tools and Resources

Experimental Reagents

Model Systems

Database Resources

Cross-Links

See Also

References

💬 Discussion

📗 Cite This Artifact

UBXD5 — UBX Domain Containing 5

UBXD5 — UBX Domain Containing 5

Introduction

Gene Structure and Protein Architecture

UBXD5 — UBX Domain Containing 5

Introduction

Gene Structure and Protein Architecture

Molecular Functions

ER-Associated Degradation (ERAD)

Aggresome Targeting and Autophagy

VCP/p97 Complex Regulation

Expression and Cellular Localization

Tissue Distribution

Subcellular Localization

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Protein Aggregation Disorders

Therapeutic Implications

Targeting the VCP-UBXD5 Axis

Small Molecule Approaches

Gene Therapy Approaches

Clinical Development

Biomarkers and Patient Selection

Research Tools and Resources

Experimental Reagents

Model Systems

Database Resources

Cross-Links

Related Genes and Proteins

Related Mechanisms

Related Diseases

See Also

References

💬 Discussion